Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | CCR8 | P51685 | 6/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1337152 | 0.89 | KDM4E (0.41) | TP53CCR8SMN1; SMN2MEN1KMT2A | |
| SCHEMBL1338897 | 0.86 | CCR8 (0.53) | TP53CCR8MEN1KMT2AHTT | |
| SCHEMBL1338666 | 0.80 | CCR8 (0.68) | TP53CCR8POLBNPC1RAB9A | |
| SCHEMBL1855816 | 0.77 | KMT2A (0.57) | CCR8MEN1KMT2ACA1CA2 | |
| SCHEMBL29469801 | 0.77 | KMT2A (0.57) | CCR8MEN1KMT2ACA1CA2 | |
| SCHEMBL1338726 | 0.77 | CYP1A2 (0.56) | CCR8KMT2APOLBJAK2TYK2 | |
| SCHEMBL1339455 | 0.76 | NPC1 (0.60) | TP53CCR8POLBNPC1RAB9A | |
| SCHEMBL1339206 | 0.76 | CCR8 (0.74) | CCR8HTT | |
| SCHEMBL1338922 | 0.76 | CCR8 (0.57) | CCR8 | |
| SCHEMBL1339130 | 0.75 | LMNA (0.48) | TP53CCR8SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063222-B2 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20090275556-A1 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | MILLENNIUM PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7491827-B2 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7378525-B2 | CCR8 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-05-27 | — | — | US | disclosed |
| US-7329755-B2 | especially naphthalene sulfonamides, used for treating asthma | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| EP-1590327-A1 | CCR8 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-02 | — | — | EP | disclosed |
| EP-1581511-A1 | CCR8 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20050085518-A1 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | MILLENNIUM PHARMACEUTICALS, INC. | 2005-04-21 | — | — | US | disclosed |
| US-20040224978-A1 | CCR8 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. | 2004-11-11 | — | — | US | disclosed |
| US-20040209948-A1 | CCR8 Inhibitors | MILLENNIUM PHARMACEUTICALS, INC. | 2004-10-21 | — | — | US | disclosed |
| WO-2004058709-A1 | CCR8 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004058736-A1 | CCR8 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085518-A1 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | CCR8, CCR1, CCR3 | TP53 4047/4885CCR8 1/4885SMN1; SMN2 3991/4885 |
| US-20090275556-A1 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | CCR8, CCR1, CCR3 | TP53 4170/4885CCR8 1/4885SMN1; SMN2 3944/4885 |
| US-20040209948-A1 | CCR8 Inhibitors | CCR8, CCR1, CCR3 | TP53 4556/4885CCR8 1/4885SMN1; SMN2 3175/4885 |
| US-20040224978-A1 | CCR8 inhibitors | CCR8, CCR1, CCRL2 | TP53 3240/4885CCR8 1/4885SMN1; SMN2 2454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.